Osimertinib: First Global Approval

456PPRECLINICAL EVIDENCE AND CLINICAL CASES OF AZD9291 ACTIVITY IN EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC) BRAIN METASTASES (BM)

(2017) D. Kim et al.   ANNALS OF ONCOLOGY

1270PLEVELS OF EGFR T790M IN PLASMA DNA AS A PREDICTIVE BIOMARKER FOR RESPONSE TO AZD9291, A MUTANT-SELECTIVE EGFR KINASE INHIBITOR

(2017) K. Thress et al.   ANNALS OF ONCOLOGY

464PPRELIMINARY AZD9291 WESTERN AND ASIAN CLINICAL PHARMACOKINETICS (PK) IN PATIENTS (PTS) AND HEALTHY VOLUNTEERS (HV): IMPLICATIONS FOR FORMULATION, DOSE AND DOSING FREQUENCY IN PIVOTAL CLINICAL STUDIES

(2017) D. Planchard et al.   ANNALS OF ONCOLOGY

466PTARGETING RESISTANCE IN EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC): PRECLINICAL EVIDENCE SUPPORTING THE COMBINATION OF EGFR TYROSINE KINASE INHIBITORS (TKIS) AZD9291 AND GEFITINIB WITH MOLECULARLY TARGETED AGENTS AND IMMUNOTHERAPEUTICS

(2017) D. Cross et al.   ANNALS OF ONCOLOGY

LBA3 * A PHASE I STUDY OF AZD9291 IN PATIENTS WITH EGFR-TKI-RESISTANT ADVANCED NSCLC - UPDATED PROGRESSION FREE SURVIVAL AND DURATION OF RESPONSE DATA

(2015) P. A. Janne et al.   ANNALS OF ONCOLOGY

EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients

(2015) D. Planchard et al.   ANNALS OF ONCOLOGY

Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer

(2015) Bin-Chi Liao et al.   CURRENT OPINION IN ONCOLOGY

3113 AZD9291 in pre-treated patients with T790M positive advanced non-small cell lung cancer (NSCLC): Pooled analysis from two Phase II studies

(2015) G.D. Goss et al.   EUROPEAN JOURNAL OF CANCER

1551 Patient experience of symptoms and side effects when treated with AZD9291 for advanced non-small-cell lung cancer: A qualitative interview sub-study

(2015) A. Ryden et al.   EUROPEAN JOURNAL OF CANCER

3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies

(2015) M.J. Ahn et al.   EUROPEAN JOURNAL OF CANCER

Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer

(2015) Chee-Seng Tan et al.   LANCET ONCOLOGY

Abstract B153: Effect of food and gastric pH modifiers on the pharmacokinetics of AZD9291

(2015) Karthick Vishwanathan et al.   MOLECULAR CANCER THERAPEUTICS

Abstract PR07: AZD9291 activity in patients with leptomeningeal disease from non-small cell lung cancer: a Phase I study

(2015) Dae Ho Lee et al.   MOLECULAR CANCER THERAPEUTICS

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

(2015) Kenneth S Thress et al.   NATURE MEDICINE

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

(2015) Pasi A. Jänne et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug–drug interactions

(2014) Solange Peters et al.   CANCER TREATMENT REVIEWS

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

(2014) D. A. E. Cross et al.   Cancer Discovery